CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its drug discovery and development programs and provide a general corporate overview at the 11th Annual Massachusetts Biotechnology Investors Forum on Tuesday, October 6, 2009, at 3:40 p.m. (ET) at the Sheraton Hotel in Boston.
